Cargando…
Inhibition of Myostatin Reduces Collagen Deposition in a Mouse Model of Oculopharyngeal Muscular Dystrophy (OPMD) With Established Disease
BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is a late-onset muscle disease presented by ptosis, dysphagia, and limb weakness. Affected muscles display increased fibrosis and atrophy, with characteristic inclusion bodies in the nucleus. Myostatin is a negative regulator of muscle mass, and...
Autores principales: | Harish, Pradeep, Forrest, Leysa, Herath, Shanti, Dickson, George, Malerba, Alberto, Popplewell, Linda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066371/ https://www.ncbi.nlm.nih.gov/pubmed/32194441 http://dx.doi.org/10.3389/fphys.2020.00184 |
Ejemplares similares
-
Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD)
por: Harish, Pradeep, et al.
Publicado: (2019) -
Novel Metabolomic Approach for Identifying Pathology-Specific Biomarkers in Rare Diseases: A Case Study in Oculopharyngeal Muscular Dystrophy (OPMD)
por: Harish, Pradeep, et al.
Publicado: (2023) -
P-7
Clinical and electrophysiological feature of 13
Italian patients with oculopharyngeal muscular
dystrophy (OPMD)
por: Fiorillo, C., et al.
Publicado: (2011) -
PABPN1 gene therapy for oculopharyngeal muscular dystrophy
por: Malerba, A., et al.
Publicado: (2017) -
Oculopharyngeal muscular dystrophy or oculopharyngeal distal myopathy: case report()
por: Maeda, Marilia Yuri, et al.
Publicado: (2015)